Alembic Pharma USFDA approvals lift oncology focus in 2026

Key development and why it matters

Alembic Pharmaceuticals has reported multiple regulatory milestones in the US over the past year, spanning oncology injectables and specialty generics. The latest trigger for the stock was US Food and Drug Administration (USFDA) approval for Methotrexate Injection, a product used in cancer treatment and certain autoimmune conditions. Such approvals matter because they expand the company’s US generics portfolio and can improve the mix toward products that typically face fewer competitors than standard oral solids. In the Indian market, USFDA updates often act as near-term price catalysts because they signal potential launches and incremental revenue streams.

Methotrexate Injection: final approval and stock reaction

Alembic said it received final USFDA approval for Methotrexate Injection. Following the announcement, the company’s shares rose by over 1.5% to ₹747.10 on 16 April 2026 at 12:53 pm. The company also indicated that the approval allows it to sell a generic version of a key drug in the US. Methotrexate is widely used across oncology and autoimmune indications, which helps explain steady baseline demand for the molecule globally.

Market sizing: US opportunity for Methotrexate Injection

Based on IQVIA data cited, the approval gives Alembic access to an estimated US market of about $15 million for the product. The article notes that while the number is not large in absolute terms, injectable generics often have relatively lower competition and can offer better margins than many oral medicines. Beyond the US, the global methotrexate market was valued at around $155 million in 2024 and is expected to grow to about $181 million by 2032, according to the provided data. The demand trend is linked to rising cancer incidence and growing prevalence of autoimmune diseases.

Bosutinib Tablets 400 mg: tentative approval and trading levels

In a separate disclosure, Alembic Pharmaceuticals announced it had secured tentative USFDA approval for Bosutinib Tablets, 400 mg. The company said the tentative approval was for its supplemental Abbreviated New Drug Application (sANDA). At around 2:34 PM, the stock was trading marginally lower at ₹799.30 per share compared with the previous close of ₹799.95 on NSE. During the session referenced, the stock touched an intraday high of ₹804.15 and an intraday low of ₹786.

Bosutinib lifecycle expansion and market size

Alembic also stated it had already secured final USFDA approvals for Bosutinib Tablets in 100 mg and 500 mg strengths. The 400 mg dosage was described as an additional opportunity in the molecule’s lifecycle. As per company-disclosed details in the text, Bosutinib Tablets, 400 mg, had an estimated US market size of $151 million for the year ended September 2025. The update is relevant because oncology molecules often have demand across multiple dose strengths, and approvals across the range can support a broader commercial footprint.

Doxorubicin Hydrochloride Liposome Injection: final ANDA nod

Alembic Pharmaceuticals also received final USFDA approval for its abbreviated new drug application (ANDA) for Doxorubicin Hydrochloride Liposome Injection. The approved dosage strengths are 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) in single-dose vials. The company stated the product is therapeutically equivalent to the reference listed drug (RLD), Doxil Liposome Injection, developed by Baxter Healthcare Corporation. The injection is indicated for ovarian cancer, AIDS-related Kaposi’s sarcoma, and multiple myeloma, with the note to refer to the label for detailed indications.

Doxorubicin approval: market size and sharp price moves

IQVIA data cited in the text estimated the US market size for Doxorubicin Hydrochloride Liposome Injection at about $19 million for the twelve months ending March 2025. The approval triggered strong price action across reports: one update noted the stock was at ₹1,002.80 at 09:21 hrs, up ₹30.95 or 3.18% on the day. Other reports described intraday gains of over 12%, and a session move of 13.61% with the stock touching a high of ₹1,104.10. In another reference, the stock rose as much as 14% to an intraday high of ₹1,106.70.

Regulatory track record and portfolio scale

With the Doxorubicin approval, Alembic said it now has 224 ANDA approvals from the USFDA, comprising 201 final approvals and 23 tentative approvals. This count provides context on the company’s execution pace in the US generics market and the breadth of its filings and clearances. A disclosed market capitalisation figure also places the company among mid-cap pharmaceutical players, with market cap reported at ₹19,102.99 crore as of June 30.

Stock performance indicators cited in the reports

The text also included technical and performance datapoints cited alongside the regulatory newsflow. Alembic’s stock was described as being on a steady uptrend, with gains of 22.7% over one year, 2.5% over six months, 15.7% over three months, and 6.8% over one month in one report. Technical indicators cited included an RSI of 52.4 and a MACD of 2.4, with the stock trading above key simple moving averages from 5-day to 200-day. The 52-week high was cited as ₹1,296.15 on October 9, 2024, and the 52-week low as ₹725.60 on March 3, 2025.

Snapshot table: approvals, market size, and stock moves

Market impact: what investors appear to be pricing in

Across the updates, the immediate market impact was visible through short-term share price spikes after USFDA approvals. The text explicitly notes that the rise in the share price reflected that investors welcomed the news. The strongest moves were associated with the Doxorubicin Liposome Injection approval, which sits in a high-value and competitive oncology injectable segment. Meanwhile, Methotrexate Injection added a smaller but steady US opportunity, and Bosutinib’s 400 mg tentative approval was positioned as a lifecycle expansion alongside already approved strengths.

Analysis: why injectables and oncology filings get attention

The approvals highlighted include injectables and oncology-focused products, categories that can be operationally complex and often have higher barriers to entry than straightforward oral generics. That complexity is one reason the market tends to react quickly when an approval is announced, especially for products described as having fewer competitors or better margins. The dataset also shows how investors track not just approvals, but the total ANDA count, mix of final versus tentative approvals, and the estimated US market sizes cited from IQVIA.

Conclusion

Alembic Pharmaceuticals’ recent USFDA milestones span Methotrexate Injection final approval, Bosutinib 400 mg tentative approval, and Doxorubicin Hydrochloride Liposome Injection final ANDA approval. The announcements were followed by measurable stock reactions, ranging from a more than 1.5% rise after Methotrexate to double-digit intraday gains tied to the Doxorubicin approval. Going forward, investors are likely to track how these approvals translate into launches and whether Alembic adds further final approvals to its stated base of 224 USFDA ANDA clearances.